50 results
8-K
EX-10.1
m3iaz
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
07ez703h
24 Mar 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-99.1
vqi76 j4k4dlnmwp86
26 Jan 22
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
8:15am
424B5
fqlmrdlpk
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-1.1
0rmjth28
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
kvts1rz
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am